Baxalta, the biopharmaceutical spinoff of Baxter, entered into a $1.7 B deal with Precision BioSceinces for 6 CAR-T (Chimeric Antigen Receptor T-cell) projects, and Saronic Biotechnology announced positive data in preclinical studies of its autologous dendritic cell vaccine for hepatocellular carcinoma. Continue reading
Tag Archives: Pfizer
Exploiting the Tumor Microenvironment – Threshold, Bioatla, Pfizer
Two companies announced news last week regarding their efforts to treat cancer by administering treatments that become activated by physiological conditions specific to the tumor microenvironment. Threshold Pharmaceuticals announced data from Phase III clinical trials of evophosphamide (TH-302), and BioAtla announced an antibody development deal with Pfizer. Continue reading